Blog
RSS FeedPosted by Michael Wonder on 11 Jun 2019
Systematic literature review calls economic impact of switching to biosimilars "uncertain"
10 June 2019 - Biosimilar drugs are intended by their developers to provide a cost-saving alternative to brand-name biologics, and ...
Posted by Michael Wonder on 10 Jun 2019
The $2.1 million question: what are the medical, ethical implications of the world's priciest drug?
10 June 2019 - With last month’s FDA approval, Zolgensma became the world’s most expensive medication. ...
Posted by Michael Wonder on 05 Jun 2019
Paying for CAR-T therapy amidst limited health system resources
3 June 2019 - CAR-T is paving a new path toward achieving access and reimbursement within limited health-system resources. How do ...
Posted by Michael Wonder on 03 Jun 2019
Australians’ lives have a price – a ‘quality-adjusted life year’ worth about $50,000
3 June 2019 - How much is your life worth? What would you pay to keep it? More importantly, what would ...
Posted by Michael Wonder on 29 May 2019
Cost effectiveness analysis in the context of US commercial health insurance
29 May 2019 - Discussions of the cost effectiveness of medical services often are couched in the framework of a ...
Posted by Michael Wonder on 25 May 2019
ICER comments on the FDA approval of Zolgensma for the treatment of spinal muscular atrophy
24 May 2019 - ICER’s update reflects the gene therapy’s new clinical data and FDA label. ...
Posted by Michael Wonder on 22 May 2019
Extending VBP models into Medicaid drug purchasing: challenges and opportunities
22 May 2019 - Over the past decade, both public and private payers have increasingly sought to develop payment policies that ...
Posted by Michael Wonder on 21 May 2019
Official Information Act response: adrenaline auto-injector cost utility analysis
20 May 2019 - PHARMAC responds to a request for any cost utility analyses performed by PHARMAC in relation to ...
Posted by Michael Wonder on 21 May 2019
Extremely high drug prices should be reviewed for appropriateness
21 May 2019 - As medicine advances, a succession of highly efficacious but extremely costly therapeutic drugs have arrived on ...
Posted by Michael Wonder on 20 May 2019
Europe responding to gene therapy challenge, but picture remains fragmented
20 May 2019 - Germany, Italy and England using outcomes-based deals. ...
Posted by Michael Wonder on 20 May 2019
ICER plans cloud-based tools to accelerate the use of value assessments in the US health care system
20 May 2019 - With a late 2019 launch target, ICER’s Evidence Compendium and Interactive Modeler will enable decision-makers within payers, ...
Posted by Michael Wonder on 10 May 2019
What do transformational shifts mean in terms of ultimate outcomes and ‘value’ of medicines?
9 May 2019 - Emerging ‘one-time’ curative therapies create important new options for patients living with difficult and incurable health ...
Posted by Michael Wonder on 02 May 2019
ICER seeks public input for 2020 value assessment framework
2 May 2019 - Accepting Open Input Through 10 June 2019. ...
Posted by Michael Wonder on 01 May 2019
Drug maker Takeda to introduce value-based pricing in Europe
29 April 2019 - Japanese company to refund Crohn's disease patients with no improvements. ...
Posted by Michael Wonder on 12 Apr 2019
Addressing health system values in health technology assessment: the use of evidence-informed deliberative processes
8 April 2019 - Health technology assessment is increasingly used around the globe to inform resource allocation decisions. Furthermore, the importance ...